{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:54:31Z","timestamp":1788980071156,"version":"build-2803163510"},"reference-count":229,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["21K09695"],"award-info":[{"award-number":["21K09695"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.addr.2023.114870","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T12:00:46Z","timestamp":1683720046000},"page":"114870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Recent advances and future prospects: Current status and challenges of the intraocular injection of drugs for vitreoretinal diseases"],"prefix":"10.1016","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8241-5378","authenticated-orcid":false,"given":"Noriyasu","family":"Hashida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.114870_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2013.02.001","article-title":"Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions","volume":"34","author":"Klaassen","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.114870_b0010","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b0015","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b0020","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ICU.0000000000000850","article-title":"Complications of intravitreal injections: 2022","volume":"33","author":"Patel","year":"2022","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0030","doi-asserted-by":"crossref","unstructured":"B. Leclercq, D. Mejlachowicz, F. Behar-Cohen, Ocular Barriers and Their Influence on Gene Therapy Products Delivery, Pharmaceutics 2022, Vol. 14, Page 998. 14 (2022) 998. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14050998.","DOI":"10.3390\/pharmaceutics14050998"},{"key":"10.1016\/j.addr.2023.114870_b0035","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.114870_b0040","first-page":"135","article-title":"Current and future ophthalmic drug delivery systems","volume":"13","author":"del Amo","year":"2008","journal-title":"A shift to the posterior segment, Drug Discovery Today."},{"key":"10.1016\/j.addr.2023.114870_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/bpb.28.1","article-title":"Advances in the cell biology of transport via the inner blood-retinal barrier: establishment of cell lines and transport functions","volume":"28","author":"Hosoya","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2023.114870_b0050","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1517\/17425247.2011.628983","article-title":"Strategies for therapy of retinal diseases using systemic drug delivery: relevance of transporters at the blood-retinal barrier","volume":"8","author":"Hosoya","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114870_b0055","first-page":"42","article-title":"Barrier analysis of periocular drug delivery to the posterior segment, Journal of Controlled Release : Official Journal of the Controlled Release","volume":"148","author":"Ranta","year":"2010","journal-title":"Society"},{"key":"10.1016\/j.addr.2023.114870_b0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.addr.2017.07.002","article-title":"Drug delivery devices for retinal diseases","volume":"128","author":"Kaji","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114870_b0065","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1007\/s11095-012-0822-5","article-title":"Prediction of the vitreal half-life of small molecular drug-like compounds","volume":"29","author":"Kidron","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.114870_b0070","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0075","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1097\/IAE.0000000000000726","article-title":"INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONS","volume":"35","author":"Yang","year":"2015","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"10.1016\/j.addr.2023.114870_b0080","doi-asserted-by":"crossref","unstructured":"C.H. Tsai, P.Y. Wang, I.C. Lin, H. Huang, G.S. Liu, C.L. Tseng, Ocular Drug Delivery: Role of Degradable Polymeric Nanocarriers for Ophthalmic Application, International Journal of Molecular Sciences 2018, Vol. 19, Page 2830. 19 (2018) 2830. https:\/\/doi.org\/10.3390\/IJMS19092830.","DOI":"10.3390\/ijms19092830"},{"key":"10.1016\/j.addr.2023.114870_b0085","first-page":"342","article-title":"Novel Ocular Drug Delivery Systems: An Update on Microemulsions, Journal of Ocular Pharmacology and Therapeutics : The Official Journal of the Association for Ocular","volume":"36","author":"\u00dcst\u00fcnda\u01e7 Okur","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.114870_b0090","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/1061186X.2021.1878366","article-title":"A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances","volume":"29","author":"Wang","year":"2021","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2023.114870_b0095","first-page":"1","article-title":"Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2023.114870_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.15171\/bi.2016.07","article-title":"Advanced drug delivery and targeting technologies for the ocular diseases","volume":"6","author":"Barar","year":"2016","journal-title":"Bioimpacts"},{"key":"10.1016\/j.addr.2023.114870_b0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.preteyeres.2004.02.003","article-title":"Drug delivery systems for vitreoretinal diseases","volume":"23","author":"Yasukawa","year":"2004","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.114870_b0110","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/00007611-197610000-00013","article-title":"The Ocusert pilocarpine system: advantages and disadvantages","volume":"69","author":"Pollack","year":"1976","journal-title":"South. Med. J."},{"key":"10.1016\/j.addr.2023.114870_b0115","first-page":"206","article-title":"Management of chronic glaucoma with pilocarpine Ocuserts","volume":"97","author":"Hillman","year":"1977","journal-title":"Trans. Ophthalmol. Soc. U. K."},{"key":"10.1016\/j.addr.2023.114870_b0120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ophtha.2004.10.042","article-title":"Intraocular pressure elevation after intravitreal triamcinolone acetonide injection","volume":"112","author":"Jonas","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0125","unstructured":"K.G. Falavarjani, Implantable Posterior Segment Drug Delivery Devices; Novel Alternatives to Currently Available Treatments, Journal of Ophthalmic & Vision Research. 4 (2009) 191. \/pmc\/articles\/PMC3498569\/ (accessed August 29, 2022)."},{"key":"10.1016\/j.addr.2023.114870_b0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199707103370203","article-title":"and the Ganciclovir Implant Study Group, Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant","volume":"337","author":"Musch","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"1992","key":"10.1016\/j.addr.2023.114870_b0135","first-page":"188","article-title":"Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device, Archives of Ophthalmology (Chicago","volume":"110","author":"Sanborn","year":"1960","journal-title":"Ill."},{"key":"10.1016\/j.addr.2023.114870_b0140","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0161-6420(00)00466-8","article-title":"Fluocinolone acetonide sustained drug delivery device to treat severe uveitis","volume":"107","author":"Jaffe","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0145","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0150","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/00006982-200004000-00015","article-title":"Dexamethasone sustained drug delivery implant for the treatment of severe uveitis","volume":"20","author":"Jaffe","year":"2000","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"10.1016\/j.addr.2023.114870_b0155","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2147\/OPTH.S209395","article-title":"Dexamethasone Intravitreal Implant for the Treatment of Macular Edema and Uveitis: A Comprehensive Narrative Review","volume":"16","author":"Kishore","year":"2022","journal-title":"Clinical Ophthalmology (Auckland, N.Z.)"},{"key":"10.1016\/j.addr.2023.114870_b0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40265-013-0010-x","article-title":"Fluocinolone acetonide intravitreal implant (Iluvien\u00ae): in diabetic macular oedema","volume":"73","author":"Sanford","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.114870_b0165","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40265-017-0722-4","article-title":"Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN \u00ae): A Review in Diabetic Macular Edema","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.114870_b0170","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1073\/pnas.1018987108","article-title":"Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration","volume":"108","author":"Zhang","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2023.114870_b0175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ajo.2013.03.021","article-title":"Randomized Trial of Ciliary Neurotrophic Factor Delivered by Encapsulated Cell Intraocular Implants for Retinitis Pigmentosa","volume":"156","author":"Birch","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0180","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1167\/iovs.12-9970","article-title":"Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases","volume":"53","author":"Kauper","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114870_b0185","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2018.09.041","article-title":"Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial","volume":"126","author":"Chew","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0190","first-page":"247","article-title":"Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye, Journal of Controlled Release : Official Journal of the Controlled Release","volume":"136","author":"Hironaka","year":"2009","journal-title":"Society"},{"key":"10.1016\/j.addr.2023.114870_b0195","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10384-006-0372-7","article-title":"Intraocular concentration of intravenous prednisolone in experimental autoimmune uveoretinitis mice","volume":"50","author":"Hashida","year":"2006","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0200","doi-asserted-by":"crossref","first-page":"47544","DOI":"10.1002\/app.47544","article-title":"Self-assembled poly(ethylene glycol) methyl ether-grafted gelatin nanogels for efficient delivery of curcumin in cancer treatment","volume":"136","author":"Tran","year":"2019","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.addr.2023.114870_b0205","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jiec.2020.06.017","article-title":"A comprehensive review on polymeric hydrogel and its composite: Matrices of choice for bone and cartilage tissue engineering","volume":"89","author":"Tran","year":"2020","journal-title":"J. Ind. Eng. Chem."},{"key":"10.1016\/j.addr.2023.114870_b0210","first-page":"394","article-title":"Feasibility of drug delivery to the eye\u2019s posterior segment by topical instillation of PLGA nanoparticles","volume":"12","author":"Tahara","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.114870_b0215","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.2147\/IJN.S173198","article-title":"Gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief","volume":"13","author":"Huang","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2023.114870_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03639045.2022.2092745","article-title":"Ocular delivery of sunitinib-loaded nanoparticles doped in tragacanthic acid hydrogel in treatment of diabetic retinopathy in rats","volume":"48","author":"Pirmardvand Chegini","year":"2022","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2023.114870_b0225","first-page":"68","article-title":"Role of zinc in formulation of PLGA\/PLA nanoparticles encapsulating betamethasone phosphate and its release profile, Journal of Controlled Release : Official Journal of the Controlled Release","volume":"105","author":"Ishihara","year":"2005","journal-title":"Society"},{"issue":"2007","key":"10.1016\/j.addr.2023.114870_b0230","first-page":"887","article-title":"Clinical evaluation of the efficacy of PEG\/PG lubricant eye drops with gelling agent (HP-Guar) for the relief of the signs and symptoms of dry eye disease: a review, Drugs of Today (Barcelona","volume":"43","author":"Foulks","year":"1998","journal-title":"Spain"},{"key":"10.1016\/j.addr.2023.114870_b0235","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.addr.2005.09.004","article-title":"Topical and systemic drug delivery to the posterior segments","volume":"57","author":"Hughes","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114870_b0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1872211308666140130093301","article-title":"Drug delivery to the back of the eye following topical administration: an update on research and patenting activity","volume":"8","author":"Boddu","year":"2014","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.addr.2023.114870_b0245","doi-asserted-by":"crossref","unstructured":"K. Kagkelaris, G. Panayiotakopoulos, C.D. Georgakopoulos, Nanotechnology-based formulations to amplify intraocular bioavailability, Therapeutic Advances in Ophthalmology. 14 (2022) 25158414221112356. https:\/\/doi.org\/10.1177\/25158414221112356.","DOI":"10.1177\/25158414221112356"},{"key":"10.1016\/j.addr.2023.114870_b0250","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/DDDT.S166092","article-title":"Update in treatment of uveitic macular edema","volume":"13","author":"Koronis","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2023.114870_b0255","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.survophthal.2007.06.004","article-title":"Triamcinolone acetonide in ocular therapeutics","volume":"52","author":"Jermak","year":"2007","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0260","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ophtha.2014.05.021","article-title":"Periocular corticosteroid injections in uveitis: effects and complications","volume":"121","author":"Sen","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0265","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","article-title":"Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection","volume":"110","author":"Beer","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0270","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ajo.2004.05.028","article-title":"Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection","volume":"138","author":"Inoue","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0275","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ajo.2006.05.023","article-title":"Intravitreal triamcinolone acetonide concentration after subtenon injection","volume":"142","author":"Thomas","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0280","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9394(01)01010-8","article-title":"Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema","volume":"132","author":"Jonas","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0285","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0161-6420(02)00975-2","article-title":"Intravitreal triamcinolone for refractory diabetic macular edema","volume":"109","author":"Martidis","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0290","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s00417-002-0529-0","article-title":"Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion, Graefe\u2019s Archive for Clinical and Experimental Ophthalmology =","volume":"240","author":"Jonas","year":"2002","journal-title":"Albrecht von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie."},{"key":"10.1016\/j.addr.2023.114870_b0295","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1442-9071.2001.00360.x","article-title":"Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis","volume":"29","author":"Young","year":"2001","journal-title":"Clin. Experiment. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0300","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0161-6420(00)00658-8","article-title":"Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study","volume":"108","author":"Antcliff","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0305","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ajo.2011.02.009","article-title":"Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis","volume":"152","author":"Leder","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0310","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/IJG.0b013e31802d696f","article-title":"Frequency and risk factors for intraocular pressure elevation after posterior sub-Tenon capsule triamcinolone acetonide injection","volume":"16","author":"Iwao","year":"2007","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.addr.2023.114870_b0315","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/978-3-319-17121-0_63","article-title":"Transscleral Controlled Delivery of Geranylgeranylaceton Using a Polymeric Device Protects Rat Retina Against Light Injury","volume":"854","author":"Nagai","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.addr.2023.114870_b0320","doi-asserted-by":"crossref","DOI":"10.1007\/s10544-019-0411-z","article-title":"A multilayered sheet-type device capable of sustained drug release and deployment control","volume":"21","author":"Sato","year":"2019","journal-title":"Biomed. Microdevices"},{"key":"10.1016\/j.addr.2023.114870_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118458","article-title":"Transscleral sustained ranibizumab delivery using an episcleral implantable device: Suppression of laser-induced choroidal neovascularization in rats","volume":"567","author":"Nagai","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.114870_b0330","first-page":"383","volume":"26","author":"Spaide","year":"2006","journal-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration"},{"key":"10.1016\/j.addr.2023.114870_b0335","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejpb.2016.09.003","article-title":"Study of stability and biophysical characterization of ranibizumab and aflibercept","volume":"108","author":"Moreno","year":"2016","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik e.V."},{"key":"10.1016\/j.addr.2023.114870_b0340","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.addr.2023.114870_b0345","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nprot.2009.33","article-title":"A protocol for the culture and differentiation of highly polarized human retinal pigment epithelial cells","volume":"4","author":"Sonoda","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2023.114870_b0350","doi-asserted-by":"crossref","unstructured":"N. Yoshihara, H. Terasaki, M. Shirasawa, H. Kawano, S. Sonoda, M. Yamaguchi, T. Hashiguchi, T. Hisatomi, T. Ishibashi, T. Sakamoto, PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO, Retina (Philadelphia, Pa.). 37 (2017) 179\u2013190. https:\/\/doi.org\/10.1097\/IAE.0000000000001117.","DOI":"10.1097\/IAE.0000000000001117"},{"key":"10.1016\/j.addr.2023.114870_b0355","doi-asserted-by":"crossref","unstructured":"H. Terasaki, T. Sakamoto, M. Shirasawa, N. Yoshihara, H. Otsuka, S. Sonoda, T. Hisatomi, T. Ishibashi, Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro, Retina (Philadelphia, Pa.). 35 (2015) 1007\u20131015. https:\/\/doi.org\/10.1097\/IAE.0000000000000428.","DOI":"10.1097\/IAE.0000000000000428"},{"key":"10.1016\/j.addr.2023.114870_b0360","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.addr.2023.114870_b0365","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","article-title":"Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis","volume":"132","author":"Thulliez","year":"2014","journal-title":"JAMA Ophthalmology."},{"key":"10.1016\/j.addr.2023.114870_b0370","doi-asserted-by":"crossref","unstructured":"T. Sato, K. Emi, T. Ikeda, H. Bando, S. Sato, S. ichi Morita, T. Oyagi, K. Sawada, Severe intraocular inflammation after intravitreal injection of bevacizumab, Ophthalmology. 117 (2010) 512\u2013516. https:\/\/doi.org\/10.1016\/J.OPHTHA.2009.07.041.","DOI":"10.1016\/j.ophtha.2009.07.041"},{"key":"10.1016\/j.addr.2023.114870_b0375","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ophtha.2012.07.083","article-title":"Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China","volume":"120","author":"Wang","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0380","doi-asserted-by":"crossref","unstructured":"L. Naftali Ben Haim, E. Moisseiev, Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases, Pharmaceutics. 13 (2021). https:\/\/doi.org\/10.3390\/PHARMACEUTICS13070967.","DOI":"10.3390\/pharmaceutics13070967"},{"key":"10.1016\/j.addr.2023.114870_b0385","doi-asserted-by":"crossref","first-page":"e17140","DOI":"10.1371\/journal.pone.0017140","article-title":"Ab-Externo AAV-Mediated Gene Delivery to the Suprachoroidal Space Using a 250 Micron Flexible Microcatheter","volume":"6","author":"Peden","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114870_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2006.05.045","article-title":"Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment","volume":"142","author":"Olsen","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0395","first-page":"109","article-title":"Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model, Journal of Controlled Release : Official Journal of the Controlled Release","volume":"203","author":"Chen","year":"2015","journal-title":"Society"},{"key":"10.1016\/j.addr.2023.114870_b0400","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/mp300716t","article-title":"Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2023.114870_b0405","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.biopha.2018.10.078","article-title":"Microneedles: A smart approach and increasing potential for transdermal drug delivery system","volume":"109","author":"Waghule","year":"2019","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie."},{"key":"10.1016\/j.addr.2023.114870_b0410","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/112067219900900310","article-title":"Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD","volume":"9","author":"Algvere","year":"1999","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0415","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1167\/iovs.04-0118","article-title":"Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial","volume":"45","author":"Binder","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114870_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2011.06.007","article-title":"A free retinal pigment epithelium-choroid graft in patients with exudative age-related macular degeneration: results up to 7 years","volume":"153","author":"Van Zeeburg","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0425","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(12)60028-2","article-title":"Embryonic stem cell trials for macular degeneration: a preliminary report","volume":"379","author":"Schwartz","year":"2012","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.addr.2023.114870_b0430","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.4114","article-title":"Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration","volume":"36","author":"Da Cruz","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2023.114870_b0435","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","article-title":"Autologous Induced Stem-Cell\u2013Derived Retinal Cells for Macular Degeneration","volume":"376","author":"Mandai","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b0440","doi-asserted-by":"crossref","unstructured":"S. Sugita, M. Mandai, Y. Hirami, S. Takagi, T. Maeda, M. Fujihara, M. Matsuzaki, M. Yamamoto, K. Iseki, N. Hayashi, A. Hono, S. Fujino, N. Koide, N. Sakai, Y. Shibata, M. Terada, M. Nishida, H. Dohi, M. Nomura, N. Amano, H. Sakaguchi, C. Hara, K. Maruyama, T. Daimon, M. Igeta, T. Oda, U. Shirono, M. Tozaki, K. Totani, S. Sugiyama, K. Nishida, Y. Kurimoto, M. Takahashi, HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration, Journal of Clinical Medicine 2020, Vol. 9, Page 2217. 9 (2020) 2217. https:\/\/doi.org\/10.3390\/JCM9072217.","DOI":"10.3390\/jcm9072217"},{"key":"10.1016\/j.addr.2023.114870_b0445","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/gt.2010.29","article-title":"Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency","volume":"17","author":"Pang","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114870_b0450","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/gt.2013.64","article-title":"Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach","volume":"21","author":"Mowat","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114870_b0455","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1002\/bit.26031","article-title":"Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8","volume":"113","author":"Khabou","year":"2016","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2023.114870_b0460","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.11.4.3","article-title":"Tropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids","volume":"11","author":"McClements","year":"2022","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.addr.2023.114870_b0465","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/hum.2019.144","article-title":"Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid","volume":"31","author":"Timmers","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2023.114870_b0470","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.114870_b0475","first-page":"2535","article-title":"Adenovirus vector-mediated in vivo gene transfer into adult murine retina","volume":"35","author":"Bennett","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114870_b0480","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nm0696-649","article-title":"Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy","volume":"2","author":"Bennett","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2023.114870_b0485","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nm0898-967","article-title":"Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa","volume":"4","author":"Lewin","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2023.114870_b0490","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/77068","article-title":"Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy","volume":"25","author":"Ali","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2023.114870_b0495","first-page":"7927","article-title":"Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir, Journal of Clinical Oncology : Official Journal of the American Society of","volume":"23","author":"Ch\u00e9vez-Barrios","year":"2005","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.addr.2023.114870_b0500","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b0505","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b0510","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2023.114870_b0515","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.114870_b0520","unstructured":"J.U. Rasmussen, H., Chu, K. W., Campochiaro, P., Gehlbach, P. L., Haller, J. A., Handa, J. T., Nguyen, Q. D., & Sung, Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD), Hum Gene Ther. 12 (2001) 2029\u20132032. https:\/\/cir.nii.ac.jp\/crid\/1571417125334516224.bib?lang=ja (accessed August 23, 2022)."},{"key":"10.1016\/j.addr.2023.114870_b0525","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/hum.2006.17.167","article-title":"Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial","volume":"17","author":"Campochiaro","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2023.114870_b0530","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.gt.3302028","article-title":"Simian lentiviral vector-mediated retinal gene transfer of pigment epithelium-derived factor protects retinal degeneration and electrical defect in Royal College of Surgeons rats","volume":"10","author":"Miyazaki","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114870_b0535","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/mt.2015.68","article-title":"CNTF Gene Therapy Confers Lifelong Neuroprotection in a Mouse Model of Human Retinitis Pigmentosa","volume":"23","author":"Lipinski","year":"2015","journal-title":"Molecular Therapy : The Journal of the American Society of Gene Therapy."},{"key":"10.1016\/j.addr.2023.114870_b0540","doi-asserted-by":"crossref","first-page":"13940","DOI":"10.1073\/pnas.1936192100","article-title":"Channelrhodopsin-2, a directly light-gated cation-selective membrane channel","volume":"100","author":"Nagel","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2023.114870_b0545","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/nn1525","article-title":"Millisecond-timescale, genetically targeted optical control of neural activity","volume":"8","author":"Boyden","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.addr.2023.114870_b0550","doi-asserted-by":"crossref","first-page":"10380","DOI":"10.1523\/JNEUROSCI.3863-06.2006","article-title":"Next-generation optical technologies for illuminating genetically targeted brain circuits, The Journal of Neuroscience : The Official Journal of the Society for","volume":"26","author":"Deisseroth","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.addr.2023.114870_b0555","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.exer.2009.12.006","article-title":"Channelrhodopsin-2 gene transduced into retinal ganglion cells restores functional vision in genetically blind rats","volume":"90","author":"Tomita","year":"2010","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2023.114870_b0560","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16883-5","article-title":"Forelimb movements evoked by optogenetic stimulation of the macaque motor cortex","volume":"11","author":"Watanabe","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114870_b0565","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial recovery of visual function in a blind patient after optogenetic therapy","volume":"27","author":"Sahel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2023.114870_b0570","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/jphp.13098","article-title":"An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites","volume":"71","author":"Attia","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2023.114870_b0575","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1023\/A:1013033826974","article-title":"Preferential binding of polyethylene glycol-coated liposomes containing a novel cationic lipid, TRX-20, to human subendthelial cells via chondroitin sulfate","volume":"18","author":"Harigai","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.114870_b0580","first-page":"4282","article-title":"Novel Chondroitin Sulfate-binding Cationic Liposomes Loaded with Cisplatin Efficiently Suppress the Local Growth and Liver Metastasis of Tumor Cells in Vivo1","volume":"62","author":"Lee","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2023.114870_b0585","first-page":"1","article-title":"Ligand-Receptor-Mediated Drug Delivery: An Emerging Paradigm in Cellular Drug Targeting, Critical Reviews&trade","volume":"18","author":"Vyas","year":"2001","journal-title":"Therapeutic Drug Carrier Systems."},{"key":"10.1016\/j.addr.2023.114870_b0590","doi-asserted-by":"crossref","first-page":"660-IN10","DOI":"10.1016\/S0022-2836(64)80115-7","article-title":"Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope","volume":"8","author":"Bangham","year":"1964","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.addr.2023.114870_b0595","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbamem.2003.10.014","article-title":"Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin-mediated tumour cell adhesion in vitro, Biochimica et Biophysica Acta -","volume":"1660","author":"Zeisig","year":"2004","journal-title":"Biomembranes"},{"key":"10.1016\/j.addr.2023.114870_b0600","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0169-409X(95)00122-N","article-title":"Limethason as a lipid microsphere preparation: An overview","volume":"20","author":"Yokoyama","year":"1996","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114870_b0605","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.41.3.263","article-title":"Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion","volume":"41","author":"Mizushima","year":"1982","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2023.114870_b0610","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs - PubMed","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2023.114870_b0615","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jjco\/hyu046","article-title":"The drug discovery by nanomedicine and its clinical experience","volume":"44","author":"Matsumura","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.addr.2023.114870_b0620","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/cas.12960","article-title":"Development of polymeric micelles for targeting intractable cancers","volume":"107","author":"Nishiyama","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.addr.2023.114870_b0625","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","article-title":"Strategies, design, and chemistry in siRNA delivery systems","volume":"144","author":"Dong","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114870_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114870_b0635","first-page":"91","article-title":"Lipid nanoparticles for delivery of messenger RNA to the back of the eye, Journal of Controlled Release : Official Journal of the Controlled Release","volume":"303","author":"Patel","year":"2019","journal-title":"Society"},{"key":"10.1016\/j.addr.2023.114870_b0640","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bcmd.2005.05.002","article-title":"The immunogenicity of dendritic cell-derived exosomes","volume":"35","author":"Quah","year":"2005","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/j.addr.2023.114870_b0645","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2023.114870_b0650","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nano.2017.09.011","article-title":"Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations","volume":"14","author":"Kim","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.addr.2023.114870_b0655","doi-asserted-by":"crossref","DOI":"10.3390\/cells11162573","article-title":"Intraocular RGD-Engineered Exosomes and Active Targeting of Choroidal Neovascularization (CNV)","volume":"11","author":"Pollalis","year":"2022","journal-title":"Cells."},{"key":"10.1016\/j.addr.2023.114870_b0660","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0005-2736(01)00368-6","article-title":"Investigation of the cellular uptake of E-Selectin-targeted immunoliposomes by activated human endothelial cells, Biochimica et Biophysica Acta -","volume":"1514","author":"Kessner","year":"2001","journal-title":"Biomembranes"},{"key":"10.1016\/j.addr.2023.114870_b0665","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1021\/acs.molpharmaceut.6b00207","article-title":"Indocyanine Green-Loaded Liposomes for Light-Triggered Drug Release","volume":"13","author":"Lajunen","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2023.114870_b0670","first-page":"157","article-title":"Light activated liposomes: Functionality and prospects in ocular drug delivery, Journal of Controlled Release : Official Journal of the Controlled Release","volume":"244","author":"Lajunen","year":"2016","journal-title":"Society"},{"key":"10.1016\/j.addr.2023.114870_b0675","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.exer.2007.10.004","article-title":"High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome","volume":"86","author":"Hashida","year":"2008","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2023.114870_b0680","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","article-title":"Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies","volume":"21","author":"Ducry","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2023.114870_b0685","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.addr.2023.114870_b0690","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.114870_b0695","first-page":"78","article-title":"Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging","volume":"4","author":"Yasunaga","year":"2017","journal-title":"Bioengineering (Basel, Switzerland)."},{"key":"10.1016\/j.addr.2023.114870_b0700","doi-asserted-by":"crossref","unstructured":"S.R. Flaxman, R.R.A. Bourne, S. Resnikoff, P. Ackland, T. Braithwaite, M. V. Cicinelli, A. Das, J.B. Jonas, J. Keeffe, J. Kempen, J. Leasher, H. Limburg, K. Naidoo, K. Pesudovs, A. Silvester, G.A. Stevens, N. Tahhan, T. Wong, H. Taylor, A. Arditi, Y. Barkana, B. Bozkurt, A. Bron, D. Budenz, F. Cai, R. Casson, U. Chakravarthy, J. Choi, N. Congdon, R. Dana, R. Dandona, L. Dandona, I. Dekaris, M. Del Monte, J. Deva, L. Dreer, L. Ellwein, M. Frazier, K. Frick, D. Friedman, J. Furtado, H. Gao, G. Gazzard, R. George, S. Gichuhi, V. Gonzalez, B. Hammond, M.E. Hartnett, M. He, J. Hejtmancik, F. Hirai, J. Huang, A. Ingram, J. Javitt, C. Joslin, M. Khairallah, R. Khanna, J. Kim, G. Lambrou, V.C. Lansingh, P. Lanzetta, J. Lim, K. Mansouri, A. Mathew, A. Morse, B. Munoz, D. Musch, V. Nangia, M. Palaiou, M.B. Parodi, F.Y. Pena, T. Peto, H. Quigley, M. Raju, P. Ramulu, D. Reza, A. Robin, L. Rossetti, J. Saaddine, M. Sandar, J. Serle, T. Shen, R. Shetty, P. Sieving, J.C. Silva, R.S. Sitorus, D. Stambolian, J. Tejedor, J. Tielsch, M. Tsilimbaris, J. van Meurs, R. Varma, G. Virgili, Y.X. Wang, N.L. Wang, S. West, P. Wiedemann, R. Wormald, Y. Zheng, Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis, The Lancet Global Health. 5 (2017) e1221\u2013e1234. https:\/\/doi.org\/10.1016\/S2214-109X(17)30393-5.","DOI":"10.1016\/S2214-109X(17)30393-5"},{"key":"10.1016\/j.addr.2023.114870_b0705","first-page":"S3","article-title":"Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration","volume":"24","author":"Wykoff","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.addr.2023.114870_b0710","doi-asserted-by":"crossref","unstructured":"C.J. Flaxel, R.A. Adelman, S.T. Bailey, A. Fawzi, J.I. Lim, G.A. Vemulakonda, G. shuang Ying, Age-Related Macular Degeneration Preferred Practice Pattern\u00ae, Ophthalmology. 127 (2020) P1\u2013P65. https:\/\/doi.org\/10.1016\/J.OPHTHA.2019.09.024.","DOI":"10.1016\/j.ophtha.2019.09.024"},{"key":"10.1016\/j.addr.2023.114870_b0715","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ebiom.2018.11.029","article-title":"Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration - the potential sources and molecular cues for their recruitment and activation","volume":"38","author":"Little","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2023.114870_b0720","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","article-title":"Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors","volume":"3","author":"Pennington","year":"2016","journal-title":"Eye and Vision."},{"key":"10.1016\/j.addr.2023.114870_b0725","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/bjophthalmol-2017-311673","article-title":"Prevalence of age-related macular degeneration associated genetic risk factors and 4-year progression data in the Irish population","volume":"102","author":"Connolly","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.addr.2023.114870_b0735","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b0740","doi-asserted-by":"crossref","unstructured":"P.U. Dugel, G.J. Jaffe, P. Sallstig, J. Warburton, A. Weichselberger, M. Wieland, L. Singerman, Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology, 124(2017) 1296-1304. https:\/\/doi: 10.1016\/j.ophtha.2017.03.057.","DOI":"10.1016\/j.ophtha.2017.03.057"},{"key":"10.1016\/j.addr.2023.114870_b0745","unstructured":"S.A. Vinores, Pegaptanib in the treatment of wet, age-related macular degeneration, International Journal of Nanomedicine. 1 (2006) 263. \/pmc\/articles\/PMC2426796\/ (accessed August 24, 2022)."},{"key":"10.1016\/j.addr.2023.114870_b0750","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0755","doi-asserted-by":"crossref","unstructured":"S.B. Bloch, M. Larsen, I.C. Munch, Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010, American Journal of Ophthalmology. 153 (2012) 209-213.e2. https:\/\/doi.org\/10.1016\/J.AJO.2011.10.016.","DOI":"10.1016\/j.ajo.2011.10.016"},{"key":"10.1016\/j.addr.2023.114870_b0760","first-page":"913","article-title":"Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System, Ophthalmic Surgery, Lasers & Imaging","volume":"49","author":"Wykoff","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.addr.2023.114870_b0765","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0770","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0775","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0780","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"American Journal of Ophthalmology Case Reports."},{"key":"10.1016\/j.addr.2023.114870_b0790","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/2474126420930863","article-title":"Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab","volume":"4","author":"Witkin","year":"2020","journal-title":"Journal of Vitreoretinal Diseases."},{"key":"10.1016\/j.addr.2023.114870_b0795","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00417-021-05517-1","article-title":"Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study","volume":"260","author":"Tamashiro","year":"2022","journal-title":"Graefe\u2019s Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie."},{"key":"10.1016\/j.addr.2023.114870_b0800","doi-asserted-by":"crossref","unstructured":"J.S. Heier, A.M. Khanani, C. Quezada Ruiz, K. Basu, P.J. Ferrone, C. Brittain, M.S. Figueroa, H. Lin, F.G. Holz, V. Patel, T.Y.Y. Lai, D. Silverman, C. Regillo, B. Swaminathan, F. Viola, C.M.G. Cheung, T.Y. Wong, A. Abbey, E. Abdulaeva, P. Abraham, A. Adan Civera, H. Agostini, A. Alezzandrini, V. Alfaro, A. Almony, L. Altay, P. Amini, A. Antoszyk, E. Aradi, L. Arias, J. Arnold, R. Asaria, S. Astakhov, Y. Astakhov, C.C. Awh, C. Balaratnasingam, S. Banerjee, C. Baumal, M. Becker, R. Belfort, G. Bratko, W.Z. Bridges, J. Brown, D.M. Brown, M. Budzinskaya, S. Buffet, S. Burgess, I. Byon, C. Cagini, J. Calzada, S. Cameron, P. Campochiaro, J. Carlson, A. Carneiro, C. Chan, E. Chang, A. Chang, D. Chao, N. Chaudhry, C. Chee, A. Cheek, S.J. Chen, S.N. Chen, G. Cheung, S. Chexal, M. Chittum, D. Chow, A. Cole, B. Connolly, P.L. Cornut, S. Couvillion, C. Danzig, V. Daskalov, A. Dessouki, F. Devin, M. Dollin, R. Dolz, L. Downey, R. Dreyer, P. Dugel, D. Eichenbaum, B. Eldem, R. Engstrom, J.J. Escobar, N. Eter, D.W. Faber, N. Falk, L. Feiner, A. Fernandez Vega, P. Ferrone, M. Figueroa, H. Fine, M. Fineman, G.M. Fox, C. Francais, P. Franco, S. Fraser-Bell, N. Fung, F. Furno Sola, R. Gale, A. Garcia-Layana, J. Gasperini, M. Gawecki, F. Ghanchi, M. Gill, M. Giunta, D. Glaser, M. Goldstein, F. Gomez Ulla, F. Gomi, V. Gonzalez, J. Graff, S. Gupta, R. Guthoff, R. Guymer, A. Haas, R. Hampton, K. Hatz, K. Hayashi, J. Heier, E. Herba, V. Hershberger, P. Higgins, N. Holekamp, S. Honda, J. Howard, A. Hu, S. Huddleston, T. Iida, H. Imaizumi, Y. Ito, Y. Ito, S. Itty, G. Javey, C. Javid, T. Kaga, J. Kaluzny, S.W. Kang, K. Kapoor, L. Karabas, T. Kawasaki, P. Kelty, A. Kerenyi, A. Khanani, R. Khoramnia, R. Khurana, K. Kimura, K. Klein-Mascia, N. Kobayashi, L. Kodjikian, H. Koizumi, G. Kokame, A. Kulikov, H. Kwong, R. Kwun, T. Lai, C.C. Lai, L. Lalonde, P. Lanzetta, M. Larsen, A. Lavina, W.K. Lee, ji E. Lee, S. Lee, J. Levy, L. Lindsell, M. Liu, N. London, A. Lotery, D. Lozano Rechy, A. Luckie, D. Maberley, T. Maeno, S. Mahmood, F. Makkouk, D. Marcus, A. Margherio, H. Masse, H. Matsubara, R. Maturi, S. Mehta, G. Menon, J. Mentes, M. Michels, Y. Mitamura, P. Mitchell, Q. Mohamed, J. Mones, R. Montemayor Lobo, J. Montero, J. Moore, R. Mori, H. Morori-Katz, R. Mukherjee, T. Murata, M. Muzyka-Wozniak, M. Nardi, N. Narendran, M. Nicolo, J. Nielsen, T. Nishimura, K. Noda, A. Nowinska, H. Oh, M. Ohr, A. Okada, P. Oleksy, S. Ono, S. Ozdek, B. Ozturk, L. Pablo, K.H. Park, D.W. Parke, M.C. Parravano, P. Patel, A. Patel, S. Patel, S. Patel, D. Pauleikhoff, I. Pearce, J. Pearlman, I. Petkova, D. Pieramici, N. Pozdeyeva, J. Qureshi, D. Raczynska, J. Ramirez Estudillo, R. Rathod, H. Razavi, G. Reilly, F. Ricci, R. Rich, B. Romanowska-Dixon, I. Rosenblatt, J.M. Ruiz Moreno, S. Sacu, H. Saedon, U. Saeed, M. Sagong, T. Sakamoto, S. Sandhu, L. Sararols, M. Saravia, R. Schadlu, P. Schlottmann, T. Sekiryu, A. Seres, F. Sermet, S. Shah, R. Shah, A. Shah, T. Sheidow, V. Sheth, C. Shiragami, B. Sikorski, R. Silva, L. Singerman, R. Sisk, T.L. S\u00f8rensen, E. Souied, D.J. Spinak, G. Staurenghi, R. Steinmetz, G. Stoller, R. Stoltz, E. Suan, I. Suner, Y. Suzanne, R. Tadayoni, K. Takahashi, K. Takayama, A. Taleb, J. Talks, H. Terasaki, J. Thompson, E. Toth-Molnar, K. Tran, R. Tuli, E. Uchiyama, A. Vajas, J. Van Lith-Verhoeven, B. Varsanyi, G. Virgili, G. Vogt, M. V\u00f6lker, D. Warrow, P. Weber, J.A. Wells, S. Wickremasinghe, M. Wieland, G. Williams, T. Williams, D. Wong, K. Wong, J. Wong, I. Wong, R. Wong, B. Wowra, C.C. Wykoff, A. Yamashita, K. Yasuda, G. Yilmaz, G. Yiu, A. Yoneda, Y.H. Yoon, B. Yoreh, H.G. Yu, S.Y. Yu, T. Yurieva, A. Zambrano, B. Zatorska, C. Zeolite, Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials, The Lancet. 399 (2022) 729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"10.1016\/j.addr.2023.114870_b0805","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ajo.2004.10.004","article-title":"Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy","volume":"139","author":"Watanabe","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0810","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1167\/iovs.18-25307","article-title":"Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability","volume":"59","author":"Rodrigues","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114870_b0815","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2147\/DDDT.S295223","article-title":"Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration","volume":"15","author":"Hussain","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2023.114870_b0820","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41433-019-0607-8","article-title":"Abicipar pegol: the non-monoclonal antibody anti-VEGF","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.addr.2023.114870_b0825","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2022.05.011","article-title":"Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab","author":"Awh","year":"2022","journal-title":"Ophthalmology. Retina."},{"key":"10.1016\/j.addr.2023.114870_b0835","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0840","first-page":"775","article-title":"End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration, Ophthalmology","volume":"5","author":"Khanani","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.addr.2023.114870_b0845","first-page":"257","article-title":"Refill-Exchange Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Trial Experience, Ophthalmic Surgery, Lasers & Imaging","volume":"53","author":"Khanani","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.addr.2023.114870_b0850","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/07853890.2022.2066169","article-title":"New frontiers of retinal therapeutic intervention: a critical analysis of novel approaches","volume":"54","author":"Nanegrungsunk","year":"2022","journal-title":"Ann. Med."},{"key":"10.1016\/j.addr.2023.114870_b0855","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ophtha.2015.09.036","article-title":"Natural History of Geographic Atrophy Progression Secondary to Age-Related Macular Degeneration (Geographic Atrophy Progression Study)","volume":"123","author":"Schmitz-Valckenberg","year":"2016","journal-title":"Ophthalmology"},{"issue":"2015","key":"10.1016\/j.addr.2023.114870_b0860","first-page":"3382","article-title":"Retinal Pigment Epithelial Cells Mitigate the Effects of Complement Attack by Endocytosis of C5b\u20139, Journal of Immunology (Baltimore","volume":"195","author":"Georgiannakis","year":"1950","journal-title":"MD"},{"key":"10.1016\/j.addr.2023.114870_b0865","doi-asserted-by":"crossref","unstructured":"L.G. Fritsche, W. Igl, J.N.C. Bailey, F. Grassmann, S. Sengupta, J.L. Bragg-Gresham, K.P. Burdon, S.J. Hebbring, C. Wen, M. Gorski, I.K. Kim, D. Cho, D. Zack, E. Souied, H.P.N. Scholl, E. Bala, K. ELee, D.J. Hunter, R.J. Sardell, P. Mitchell, J.E. Merriam, V. Cipriani, J.D. Hoffman, T. Schick, Y.T.E. Lechanteur, R.H. Guymer, M.P. Johnson, Y. Jiang, C.M. Stanton, G.H.S. Buitendijk, X. Zhan, A.M. Kwong, A. Boleda, M. Brooks, L. Gieser, R. Ratnapriya, K.E. Branham, J.R. Foerster, J.R. Heckenlively, M.I. Othman, B.J. Vote, H.H. Liang, E. Souzeau, I.L. McAllister, T. Isaacs, J. Hall, S. Lake, D.A. Mackey, I.J. Constable, J.E. Craig, T.E. Kitchner, Z. Yang, Z. Su, H. Luo, D. Chen, H. Ouyang, K. Flagg, D. Lin, G. Mao, H. Ferreyra, K. Stark, C.N. Von Strachwitz, A. Wolf, C. Brandl, G. Rudolph, M. Olden, M.A. Morrison, D.J. Morgan, M. Schu, J. Ahn, G. Silvestri, E.E. Tsironi, K.H. Park, L.A. Farrer, A. Orlin, A. Brucker, M. Li, C.A. Curcio, S. Mohand-Sa\u2019d, J.A. Sahel, I. Audo, M. Benchaboune, A.J. Cree, C.A. Rennie, S. V. Goverdhan, M. Grunin, S. Hagbi-Levi, P. Campochiaro, N. Katsanis, F.G. Holz, F. Blond, H. Blanch\u00e9, J.F. ois Deleuze, R.P. Igo, B. Truitt, N.S. Peachey, S.M. Meuer, C.E. Myers, E.L. Moore, R. Klein, M.A. Hauser, E.A. Postel, M.D. Courtenay, S.G. Schwartz, J.L. Kovach, W.K. Scott, G. Liew, A.G. Tan, B. Gopinath, J.C. Merriam, R.T. Smith, J.C. Khan, H. Shahid, A.T. Moore, J.A. McGrath, R. Laux, M.A. Brantley, A. Agarwal, L. Ersoy, A. Caramoy, T. Langmann, N.T.M. Saksens, E.K. Jong, C.B. Hoyng, M.S. Cain, A.J. Richardson, T.M. Martin, J. Blangero, D.E. Weeks, B. Dhillon, C.M. Van Duijn, K.F. Doheny, J. Romm, C.C.W. Klaver, C. Hayward, M.B. Gorin, M.L. Klein, P.N. Baird, A.I. Den Hollander, S. Fauser, J.R. WYates, R. Allikmets, J.J. Wang, D.A. Schaumberg, B.E.K. Klein, S.A. Hagstrom, I. Chowers, A.J. Lotery, T. L\u00e9veillard, K. Zhang, M.H. Brilliant, A.W. Hewitt, A. Swaroop, E.Y. Chew, M.A. Pericak-Vance, M. DeAngelis, D. Stambolian, J.L. Haines, S.K. Iyengar, B.H.F. Weber, G.R. Abecasis, I.M. Heid, A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants, Nature Genetics. 48 (2016) 134\u2013143. https:\/\/doi.org\/10.1038\/NG.3448.","DOI":"10.1038\/ng.3448"},{"key":"10.1016\/j.addr.2023.114870_b0870","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0875","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ophtha.2021.02.025","article-title":"Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy","volume":"128","author":"Wykoff","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0880","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaophthalmol.2021.6067","article-title":"Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial","volume":"140","author":"Nittala","year":"2022","journal-title":"JAMA Ophthalmology."},{"key":"10.1016\/j.addr.2023.114870_b0885","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.298.8.902","article-title":"Management of diabetic retinopathy: a systematic review","volume":"298","author":"Mohamed","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2023.114870_b0890","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.114870_b0895","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.114870_b0900","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/cxo.12552","article-title":"Diabetic macular oedema: clinical risk factors and emerging genetic influences","volume":"100","author":"Liu","year":"2017","journal-title":"Clin. Exp. Optom."},{"key":"10.1016\/j.addr.2023.114870_b0905","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamaophthalmol.2015.3055","article-title":"Extent of Exacerbation of Chronic Health Conditions by Visual Impairment in Terms of Health-Related Quality of Life","volume":"133","author":"Park","year":"2015","journal-title":"JAMA Ophthalmology."},{"key":"10.1016\/j.addr.2023.114870_b0910","doi-asserted-by":"crossref","unstructured":"C.J. Flaxel, R.A. Adelman, S.T. Bailey, A. Fawzi, J.I. Lim, G.A. Vemulakonda, G. shuang Ying, Retinal Vein Occlusions Preferred Practice Pattern\u00ae, Ophthalmology. 127 (2020) P288\u2013P320. https:\/\/doi.org\/10.1016\/J.OPHTHA.2019.09.029.","DOI":"10.1016\/j.ophtha.2019.09.029"},{"key":"10.1016\/j.addr.2023.114870_b0915","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0920","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","article-title":"The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema","volume":"122","author":"Ishibashi","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0925","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0930","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0935","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0940","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0945","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1080\/10717544.2022.2069301","article-title":"The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery","volume":"29","author":"Ranade","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2023.114870_b0950","doi-asserted-by":"crossref","unstructured":"C.C. Wykoff, F. Abreu, A.P. Adamis, K. Basu, D.A. Eichenbaum, Z. Haskova, H. Lin, A. Loewenstein, S. Mohan, I.A. Pearce, T. Sakamoto, P.G. Schlottmann, D. Silverman, J.K. Sun, J.A. Wells, J.R. Willis, R. Tadayoni, T. Aaberg, A. Abbey, E. Abdulaeva, S. Abengoechea, P. Abraham, T. Ach, S. Adams, A. Adan Civera, S. Adrean, H. Agostini, S. Alam, A. Alezzandrini, V. Alfaro, D. Aliseda, A. Almony, P. Amat, P. Amini, A. Antoszyk, L. Arias, R. Asaria, M. Avila, C.C. Awh, J. Bafalluy, C. Baker, F. Bandello, M. Barakat, K. Barraza, G. Bator, C. Baumal, R. Belfort, C. Bergstrom, G. Bertolucci, T. Bochow, M. Bolz, E. Borcz, A. Bordon, D. Boyer, G. Bratko, M. Brent, J. Brown, D.M. Brown, M. Budzinskaya, S. Buffet, S. Burgess, B. Burton, M. Busquets, F. Cabrera, C. Cagini, J. Calzada, P. Campochiaro, J. Carlson, A. Castellarin, C. Cava, V. Chaikitmongkol, C. Chan, E. Chang, J. Chang, A. Chang, S. Charles, N. Chaudhry, C. Chee, J. Chen, F. Chen, S.J. Chen, R. Cheong-Leen, A. Chiang, M. Chittum, D. Chow, B. Connolly, P.L. Cornut, K. Csaky, C. Danzig, A. Das, V. Daskalov, C. Desco, A. Dessouki, J. Dickinson, B. Do, M. Dollin, P. Dugel, J. Dusova, D. Eichenbaum, B. Eldem, R. Engstrom, J. Ernest, J.J. Escobar, S. Esposti, N. Eter, N. Falk, A. Farkas, L. Feiner, N. Feltgen, C. Fernandez, A. Fernandez Vega, P. Ferrone, J. Figueira, M. Figueroa, O. Findl, H. Fine, J. Fortun, G.M. Fox, S. Foxman, C. Framme, S. Fraser-Bell, A. Fu, A. Fukutomi, N. Fung, F. Furno Sola, R. Gallego-Pinazo, R. Garcia, A. Garcia-Layana, M. Gawecki, S. George, F. Ghanchi, G. Ghorayeb, R. Goldberg, M. Goldstein, N. Gomes, F. Gomez Ulla, V. Gonzalez, C. Greven, S. Gupta, M. Guzman, M. Harris, K. Hatz, V. Hau, V. Hau, K. Hayashi, J. Heier, E. Herba, V. Hershberger, P. Higgins, A. Hirakata, A. Ho, N. Holekamp, S. Honda, J. Hsu, A. Hu, M. Hurcikova, Y. Ikeda, R. Isernhagen, Y. Ito, T. Jackson, R. Jacoby, A. Jafree, G. Javey, C. Javid, C. Jhaveri, M. Johnson, M. Kacer\u00edk, J. Kaluzny, D. Kampik, S.W. Kang, K. Kapoor, L. Karabas, T. Kawasaki, A. Kerenyi, A. Khanani, R. Khurana, B. Kim, K. Kimura, G. Kishino, S. Kitano, K. Klein-Mascia, G. Kokame, J.F. Korobelnik, A. Kulikov, A. Kuriyan, H. Kwong, R. Kwun, T. Lai, C.C. Lai, P. Laird, L. Lalonde, P. Lanzetta, M. Larsen, C. Laugesen, D. Lavinsky, O. Lebreton, S. Lee, J. Levy, B. Lipkova, M. Liu, J. Liu, C.P. Lohmann, N. London, K. Lorenz, A. Lotery, D. Lozano Rechy, S. Lujan, P. Ma, T. Maeno, S. Mahmood, F. Makkouk, K. Malik, D. Marcus, A. Margherio, L. Mastropasqua, R. Maturi, F. McCabe, M. McKibbin, H. Mehta, G. Menon, J. Mentes, K. Michalska-Malecka, A. Misheva, Y. Mitamura, P. Mitchell, Y. Modi, Q. Mohamed, J. Montero, J. Moore, V. Morales Canton, H. Morori-Katz, T. Morugova, T. Murakami, M. Muzyka-Wozniak, M. Nardi, J. Nemcansky, K. Nester-Ostrowska, J. Neto, C. Newell, M. Nicolo, J. Nielsen, K. Noda, A. Obana, N. Ogata, H. Oh, K. Oh, M. Ohr, P. Oleksy, S. Oliver, S. Olivier, J. Osher, S. Ozcali\u015fkan, B. Ozturk, A. Papp, K.H. Park, D.W. Parke, M.C. Parravano, S. Patel, S. Patel, I. Pearce, J. Pearlman, F. Penha, I. Perente, S. Perkins, G. Pertile, I. Petkova, T. Peto, D. Pieramici, A. Pollreisz, P. Pongsachareonnont, N. Pozdeyeva, S. Priglinger, J. Qureshi, D. Raczynska, R. Rajagopalan, J. Ramirez Estudillo, P. Raskauskas, R. Rathod, H. Razavi, C. Regillo, F. Ricci, S. Rofagha, D. Romanczak, B. Romanowska-Dixon, D. Rosberger, I. Rosenblatt, B. Rosenblatt, A. Ross, P. Ruamviboonsuk, J.M. Ruiz Moreno, G. Salom\u00e3o, S. Sandhu, D. Sandner, L. Sararols, O. Sawada, R. Schadlu, P. Schlottmann, C. Schuart, B. Seitz, A. Seres, F. Sermet, S. Shah, A. Shah, R. Shah, S. Sharma, T. Sheidow, V. Sheth, A. Shimouchi, M. Shimura, B. Sikorski, R. Silva, M. Singer, L. Singerman, R. Singh, E. Souied, D.J. Spinak, G. Spital, N. Steinle, J. Stern, G. Stoller, R. Stoltz, C. Stone, A. Stone, E. Suan, M. Sugimoto, I. Sugita, J. Sun, X. Sun, I. Suner, L. Szalczer, T. Szecsko, A. Tabassian, H. Takagi, K. Takayama, A. Taleb, J. Talks, G. Tan, T. Tanabe, S. Taylor, A. Thach, J. Thompson, P. Tlucek, R. Torti, D. Tosheva Guneva, E. Toth-Molnar, E. Uchiyama, A. Vajas, D. Varma, B. Varsanyi, P. Vassileva, S. Vaz-Pereira, M. Veith, J.I. Vela, F. Viola, G. Virgili, G. Vogt, H. Vorum, P. Weber, T. Wecke, R. Wee, M. Weger, P. Weishaar, S. Wickremasinghe, T.R. Williams, T. Williams, G. Williams, A. Wolf, J. Wolfe, J. Wong, D. Wong, I. Wong, R. Wong, B. Wowra, E. Wyl\u0119ga\u0142a, C.H. Yang, T. Yasukawa, P. Yates, G. Yilmaz, G. Yiu, Y.H. Yoon, B. Yoreh, S. Yoshida, H.G. Yu, S.Y. Yu, T. Yurieva, L. Zacharias, K. Zaczek Zakrzewska, A. Zambrano, B. Zatorska, C. Zeolite, J. Zheutlin, Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials, Lancet. 399 (2022) 741\u2013755. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6.","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"10.1016\/j.addr.2023.114870_b0955","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0960","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0965","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0970","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0975","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0980","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study","volume":"97","author":"Holz","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b0985","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b0990","doi-asserted-by":"crossref","unstructured":"T. Leber, Ueber Retinitis pigmentosa und angeborene Amaurose, Archiv F\u00fcr Ophthalmologie 1869 15:3. 15 (1869) 1\u201325. https:\/\/doi.org\/10.1007\/BF02721213.","DOI":"10.1007\/BF02721213"},{"key":"10.1016\/j.addr.2023.114870_b0995","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ng0501-92","article-title":"Gene therapy restores vision in a canine model of childhood blindness","volume":"28","author":"Acland","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2023.114870_b1000","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber\u2019s congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b1005","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.114870_b1010","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b1015","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114870_b1020","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.omtn.2018.07.010","article-title":"Splice-Modulating Oligonucleotide QR-110 Restores CEP290 mRNA and Function in Human c.2991+1655A>G LCA10 Models, Molecular Therapy","volume":"12","author":"Dulla","year":"2018","journal-title":"Nucleic Acids."},{"key":"10.1016\/j.addr.2023.114870_b1025","first-page":"614","article-title":"Human genetics","volume":"347","author":"Dryja","year":"1990","journal-title":"Deficiencies in sight with the candidate gene approach, Nature."},{"key":"10.1016\/j.addr.2023.114870_b1030","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJM199011083231903","article-title":"Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa","volume":"323","author":"Dryja","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b1035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2023.114870_b1040","doi-asserted-by":"crossref","unstructured":"S. Hu, J. Du, N. Chen, R. Jia, J. Zhang, X. Liu, L. Yang, In Vivo CRISPR\/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in a Mouse Model of X-Linked Retinitis Pigmentosa, Investigative Ophthalmology & Visual Science. 61 (2020) 31\u201331. https:\/\/doi.org\/10.1167\/IOVS.61.4.31.","DOI":"10.1167\/iovs.61.4.31"},{"key":"10.1016\/j.addr.2023.114870_b1045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114870_b1050","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/hmg\/ddx438","article-title":"Cas9\/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery","volume":"27","author":"Giannelli","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2023.114870_b1055","doi-asserted-by":"crossref","DOI":"10.1038\/srep39608","article-title":"Illegitimate translation causes unexpected gene expression from on-target out-of-frame alleles created by CRISPR-Cas9","volume":"6","author":"Makino","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2023.114870_b1060","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-14181-3","article-title":"Single AAV-mediated mutation replacement genome editing in limited number of photoreceptors restores vision in mice","volume":"11","author":"Nishiguchi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114870_b1065","doi-asserted-by":"crossref","unstructured":"M.C. Seabra, M.S. Brown, J.L. Goldstein, Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase, Science (New York, N.Y.). 259 (1993) 377\u2013381. https:\/\/doi.org\/10.1126\/SCIENCE.8380507.","DOI":"10.1126\/science.8380507"},{"key":"10.1016\/j.addr.2023.114870_b1070","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0092-8674(93)90639-8","article-title":"cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein","volume":"73","author":"Andres","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.114870_b1075","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMc1509501","article-title":"Visual Acuity after Retinal Gene Therapy for Choroideremia","volume":"374","author":"Edwards","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b1080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","article-title":"Choroideremia Gene Therapy Phase 2 Clinical Trial: 24-Month Results","volume":"197","author":"Lam","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b1085","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia: A Randomized Clinical Trial","volume":"137","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b1090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/medicina57010064","article-title":"Update on Gene Therapy Clinical Trials for Choroideremia and Potential Experimental Therapies","volume":"57","author":"Abbouda","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.addr.2023.114870_b1095","doi-asserted-by":"crossref","unstructured":"Y. Nuzbrokh, S.D. Ragi, S.H. Tsang, Gene therapy for inherited retinal diseases, Annals of Translational Medicine. 9 (2021) 1278\u20131278. https:\/\/doi.org\/10.21037\/ATM-20-4726.","DOI":"10.21037\/atm-20-4726"},{"key":"10.1016\/j.addr.2023.114870_b1100","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/sj.eye.6702841","article-title":"Changing challenges in the control of blindness in children","volume":"21","author":"Gilbert","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.addr.2023.114870_b1105","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised Indications for the Treatment of Retinopathy of Prematurity: Results of the Early Treatment for Retinopathy of Prematurity Randomized Trial","volume":"121","author":"Good","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114870_b1110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b1115","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.114870_b1120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2023.114870_b1125","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.addr.2023.114870_b1130","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114870_b1135","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.addr.2023.114870_b1140","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1080\/14740338.2019.1692810","article-title":"Safety of systemic therapy for noninfectious uveitis","volume":"18","author":"Ormaechea","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.addr.2023.114870_b1145","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/bjophthalmol-2020-315911","article-title":"A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation","volume":"105","author":"Wong","year":"2021","journal-title":"Br. J. Ophthalmol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23001850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23001850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:33:06Z","timestamp":1759210386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23001850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":229,"alternative-id":["S0169409X23001850"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.114870","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances and future prospects: Current status and challenges of the intraocular injection of drugs for vitreoretinal diseases","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.114870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114870"}}